ArticleFrontiers in endocrinology2026
Effect of pericentric inversion of chromosome 9 on reproductive outcomes in assisted reproductive technology: a propensity score-matched cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pericentric inversion of chromosome 9 [inv (9)] is a common chromosomal polymorphism found in approximately 1-2% of the population. While inv(9) has been generally considered a benign variant, its potential effects on reproductive outcomes, especially in the context of assisted reproductive technology (ART), remain unclear. This study aimed to evaluate whether inv(9) affects embryologic and reproductive outcomes in ART cycles. Methods: This retrospective cohort study included 40,502 ART cycles conducted between September 2008 to December 2023, of which 903 involved couples carrying inv(9) and 39,599 involved couples with normal karyotypes (NK). Propensity score matching (PSM) was used to balance baseline characteristics. The primary outcome was live birth rate (LBR), and secondary outcomes included biochemical and clinical pregnancy, miscarriage, and neonatal outcomes among live births (multiple births and low birth weight), and cycle parameters (oocyte yield, fertilization, and blastocyst formation rates). Results: After 1:2 PSM, baseline characteristics were balanced between inv(9) and NK groups. Cycle outcomes, including oocytes retrieved (10.0 ± 7.8 vs 9.9 ± 7.5), fertilization, and blastocyst formation rates, were comparable. In fresh embryo transfer (ET) cycles, inv(9) carriers had a modestly higher live birth rate compared to NK couples (46.4% vs 41.2%; aRR = 1.13; 95% CI 1.01-1.27), while no significant differences were observed in frozen embryo transfer (FET) cycles (41.1% vs 40.0%; aRR = 1.04; 95% CI 0.93-1.17). Other pregnancy outcomes (multiple births, low birth weight, biochemical pregnancy, clinical pregnancy, and miscarriage) were similar between groups. No significant differences in live birth, clinical pregnancy, miscarriage, multiple births, or low birth weight were observed between male and female inv(9) carriers in either fresh or frozen cycles. Conclusions: Pericentric inversion of chromosome 9 was not associated with adverse embryologic or reproductive outcomes in ART. These findings support the classification of inv(9) as a benign chromosomal variant and provide reassurance that its presence does not warrant additional intervention in couples undergoing ART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.